NYSE:ABBV
AbbVie Stock News
$168.59
+2.03 (+1.22%)
At Close: Jun 14, 2024
AbbVie (ABBV) Buys Global Rights to Novel IBD Candidate
09:51am, Friday, 14'th Jun 2024
AbbVie (ABBV) signs an exclusive global licensing deal with the Chinese company FutureGen to develop FG-M701, a next-generation TL1A antibody, for IBD indications.
The Dividend Defenders: 3 Stocks That Will Protect and Grow Your Wealth Dividend Stocks
06:15am, Friday, 14'th Jun 2024
With the markets trading at all-time highs, it's natural to want to protect your gains by turning to a more defensive strategy. As we've seen throughout history, when the markets go up, they tend to p
Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
11:00am, Thursday, 13'th Jun 2024
NEW YORK, NY / ACCESSWIRE / June 13, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:CERE) and AbbVie, Inc. ("AbbV
AbbVie inks immune disorder drug licensing deal with China's FutureGen
10:01am, Thursday, 13'th Jun 2024
U.S. drugmaker AbbVie will develop and commercialize an experimental treatment for inflammatory bowel disease (IBD) from China's FutureGen Biopharmaceutical under a licensing agreement, the companies
AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease
07:59am, Thursday, 13'th Jun 2024
- Global license agreement to focus on the development of FG-M701, a TL1A antibody, for the treatment of inflammatory bowel disease (IBD) NORTH CHICAGO, Ill. and BEIJING , June 13, 2024 /PRNewswir
AbbVie, Inc. (ABBV) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)
07:12pm, Wednesday, 12'th Jun 2024
AbbVie, Inc. (NYSE:ABBV ) Goldman Sachs 45th Annual Global Healthcare Conference June 12, 2024 10:00 AM ET Company Participants Robert Michael - President & COO Jeffrey Stewart - EVP & Chief Commercia
Blue-Chip Bonanzas: 3 Industry Leaders Trading at Unbelievable Discounts
03:39pm, Wednesday, 12'th Jun 2024
When it comes to targeting discounted ideas in the equities sector, undervalued blue-chip stocks offer some of the most compelling prospects. First and foremost, blue chips earn the status through dec
US Gastroenterologists Express Anticipation for Approval of AbbVie's Skyrizi in Ulcerative Colitis, Projecting Rapid Adoption Post-Launch
12:18pm, Wednesday, 12'th Jun 2024
Despite enthusiasm for Skyrizi, key updates for various developmental assets in ulcerative colitis were released at Digestive Disease Week, holding the potential to impact sentiments. Despite enthusia
Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
11:00am, Wednesday, 12'th Jun 2024
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:CERE) and AbbVie, Inc. ("AbbV
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
10:06am, Wednesday, 12'th Jun 2024
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
11:00am, Tuesday, 11'th Jun 2024
NEW YORK, NY / ACCESSWIRE / June 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:CERE) and AbbVie, Inc. ("AbbV
BOTOX® Cosmetic (onabotulinumtoxinA) Reveals 2024 Women Entrepreneur Grant Recipients
08:00am, Tuesday, 11'th Jun 2024
For The Second Year, 20 Women Entrepreneurs Will Each Receive $25,000 In Funding, Plus Access to Mentorship and Community—Helping to Close the Confidence Gap IRVINE, Calif. , June 11, 2024 /PRNewswi
AbbVie (ABBV) Laps the Stock Market: Here's Why
06:50pm, Monday, 10'th Jun 2024
AbbVie (ABBV) closed the most recent trading day at $170.46, moving +0.61% from the previous trading session.
NEW YORK, NY / ACCESSWIRE / June 10, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:CERE) and AbbVie, Inc. ("AbbV
NEW YORK, NY / ACCESSWIRE / June 9, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:CERE) and AbbVie, Inc. ("AbbVi